Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2009/050985external-prioritypatent/WO2010009391A1/en
Application filed by Bristol Myers Squibb Co, Domantis LtdfiledCriticalBristol Myers Squibb Co
Publication of TN2011000001A1publicationCriticalpatent/TN2011000001A1/en
Disclosed are domain antibodies that monovalently bind CD28. Domain antibodies that are monovalent for binding of CD28 can inhibit CD28 activity. In one aspect, a domain antibody consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD28, in an aspect, without substantially agonizing CD28 activity. In another aspect, the domain antibody is a human domain antibody. The disclosure further encompasses methods of antagonizing CD80 and/or CD86 interactions with CD28 in an individual and methods of treating diseases or disorders involving CD80 and/or CD86 interactions with CD28, the methods involving administering a domain antibody to the individual.
TN2011000001A2009-07-172011-01-03Compositions monovalent for cd28 binding and methods of use
TN2011000001A1
(en)